Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]: Side Effects & Safety Data for 6 Drugs

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC] includes 6 drugs with a combined 61,375 adverse event reports in the FDA FAERS database. Compare their safety profiles, side effects, and outcomes below.

6
Drugs in Class
61,375
Combined Reports

All Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC] Drugs Ranked by Reports

Drug Brand Name Reports Deaths Hosp. Death Rate
TENOFOVIR DISOPROXIL Tenofovir Disoproxil Fumarate 26,978 1,235 3,617 4.6%
LAMIVUDINE Lamivudine and Zidovudine 16,685 1,838 3,442 11.0%
ZIDOVUDINE RETROVIR 6,722 816 1,067 12.1%
ABACAVIR Abacavir Sulfate 4,282 524 890 12.2%
EMTRICITABINE Truvada 3,718 499 797 13.4%
TENOFOVIR ALAFENAMIDE VEMLIDY 2,990 311 713 10.4%

Common Side Effects in Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC] Drugs

Side EffectReportsDeaths
Bone density decreased 10,668 159
Renal injury 9,323 168
Skeletal injury 8,320 172
Chronic kidney disease 7,441 221
Osteonecrosis 7,302 107
Bone loss 7,046 107
Multiple fractures 6,818 109
Renal failure 6,796 395
Foetal exposure during pregnancy 5,798 792
Osteoporosis 5,567 89
View detailed side effects for this class → Compare drugs in this class →